Exacta is a comprehensive genomic test designed to identify key genetic alterations and pathways driving the cancer, enabling us to understand which treatments might work best against it.
It is a multi-analyte and multi-coordinate investigation that integrates genomic alterations in 400 genes and perturbations in the expressions of 20,802 genes to unravel actionable mutations and pathways propelling cancer. Exacta can identify the most efficacious drugs for every individual cancer and thus enable highly sophisticated treatment strategies beyond the conventional perspective, even for difficult refractory cancers
Exacta works by analysing the genomic profile of an individual, detecting alterations in genes and shifts in the expression of the genes. This advanced analysis uncovers actionable mutations and cancer-driving pathways, as well as drug toxicity profile and chemosensitivity analysis, offering key insights to personalise the treatment strategy for that individual.
It is the most comprehensive multi-analyte test available in the market. It is clinically proven and identifies the most effective drugs for each cancer, enabling advanced treatment strategies even for difficult and unresponsive cases